FarmavitaR+

1. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing ...

2. The Top 10 Biosimilar Players
(Reports/Market Report)

... by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016. In the ...

3. Intellectual Properties Rights
(Professional Articles/Life Science Article)

... copyrights, trademarks, patents, industrial design rights and trade secrets. The majority of intellectual property rights provide creators of original works economic incentive to develop and share ideas ...

4. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... to succeed in the biosimilars sector. According to Datamonitor, the biosimilars market will grow to more than $2 billion across the seven major markets by 2014 following key patent expiries for epoetin ...

5. Generic Benchmarking
(Reports/Market Report)

Generic Benchmarking: Brand Erosion at Patent Expiry Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent ...

6. The Top 10 Generic Pharmaceutical
(Reports/Company Report)

... during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry. Rising healthcare expenditure has also contributed to industry expansion, with governments ...

7. Optimizing Brand Lifecycle Management
(Reports/Market Report)

Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition As competitive pressures from the entry of generics post-patent expiry and new ...

8. eCTD
(eSubmissions/eSubmissions)

... new revenue for the business as the firm achieves patent approval before its rivals. Automation also makes it much easier to outsource the process to a specialist agency, potentially creating even greater ...

9. Biosimilars: Benchmarking the key players
(Reports/Market Report)

With increasing regulatory clarity and high revenue potential, interest in biosimilars increases With increasing regulatory clarity and the expiries of key patents covering innovator biologics, ...

10. Update - MRP in Hungary as CMS
(Regulatory Affairs/European Union)

... product with analytical certificates if the samples cannot be submitted during the validation period, please declare to do so until day 50 of the procedure Patent Declaration in case of ...

11. Benchmarking Patent Expiries
(Reports/Company Report)

Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion at Patent Expiry With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. ...

12. Market Trends
(Reports/Market Report)

... on launch portfolio compensating for revenues loses of marketed products, due to patent expiries. Read more...  ...

13. Licensing Trends
(Reports/Company Report)

... I licensing deals made by the top 20 pharmaceutical companies. Companies facing patent expiries of key revenue drivers between 2006–12 have in-licensed products to counteract the ensuing ...

14. Key trends
(Reports/Market Report)

Key trends and events in the 7 major markets The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely ...

15. Growth Opportunities in Generics
(Reports/Market Report)

Future Growth Opportunities in Generics: Impact of consolidation on market and competitive dynamics The number of commercially lucrative drugs coming off patent has catalyzed the growth of the ...

16. The Indian Pharmaceutical Market
(Reports/Market Report)

... and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience ...

17. Patent Protection Strategies
(Reports/Market Report)

Patent Protection Strategies: Maximising product Revenues Patent Protection Strategies: Maximising product revenues explores the best methods of exploiting legislation to maximise revenue generation ...

18. The Future of Biosimilars
(Reports/Product Report)

... growth of 20%in 2006, amassing a market share of $64 billion. However, the impending patent expiry of many leading products has created a number of highly attractive market opportunities for biosimilars. ...

19. Translational Medicine in Biopharmaceutical R&D
(Reports/Market Report)

... drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency ...

20. FDA Improves Generic Drug Access
(Regulatory Affairs/North America)

... determine if they are eligible for 180-day marketing exclusivity for their products. This period of marketing exclusivity is generally provided to the first generic drug that challenges a patent for the ...